What is HC Wainwright’s Estimate for NAGE Q4 Earnings?

Niagen Bioscience, Inc. (NASDAQ:NAGE) – HC Wainwright issued their Q4 2025 EPS estimates for shares of Niagen Bioscience in a report released on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of $0.02 for the quarter. HC Wainwright also issued estimates for Niagen Bioscience’s Q2 2026 earnings at $0.09 EPS and Q4 2026 earnings at $0.13 EPS.

A number of other research firms have also issued reports on NAGE. Canaccord Genuity Group reduced their price target on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.28.

Niagen Bioscience Trading Down 4.9%

Shares of NASDAQ NAGE opened at $5.00 on Thursday. The stock has a market cap of $399.05 million, a P/E ratio of 20.83 and a beta of 2.35. The business’s fifty day simple moving average is $6.10 and its 200-day simple moving average is $7.52. Niagen Bioscience has a 12-month low of $4.93 and a 12-month high of $14.69.

Institutional Investors Weigh In On Niagen Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the business. Corient Private Wealth LLC purchased a new stake in Niagen Bioscience during the fourth quarter worth approximately $204,000. SummitTX Capital L.P. acquired a new stake in Niagen Bioscience during the fourth quarter worth approximately $79,000. Tudor Investment Corp ET AL acquired a new stake in Niagen Bioscience during the fourth quarter worth approximately $360,000. Quadrature Capital Ltd purchased a new stake in shares of Niagen Bioscience during the 4th quarter worth approximately $104,000. Finally, Man Group plc boosted its holdings in shares of Niagen Bioscience by 70.8% in the 4th quarter. Man Group plc now owns 27,105 shares of the company’s stock valued at $172,000 after buying an additional 11,239 shares in the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.